Indonesian Pharmaceutical Factory Changed Their Mind on the Uncertain Data after Saying 97% Validity for Chinese Vaccination
Brazil, Turkey and countries in East Asia Regions subsequently purchased Chinese COVID-19 vaccination which the foreign press claims it as “Chinese Vaccination Diplomatic”. Indonesia is the most frontline among these countries as they have received 1.2 million doses of CoronaVac, COVID-19 vaccinations from Sinovac Biotech in Beijing. However, Bio Forma Company, an Indonesia state-owned pharmaceutical company, pointed yesterday (Dec 8) that according to their interim data, the CoronaVac achieves 97% effectiveness, but then changed their wordings to uncertain protectiveness of the vaccine less than a day after.
An Indonesian state-owned pharmaceutical factory PT Bio Farma, co-operating with Beijing Sinovac Biotech, has announced on Tuesday (Dec 8) that the interim data of CoronaVoc phase 3 clinical test shows its 97% of effective protection without providing details.
Sinovac Biotech immediately issued a statement that they have not received data on the effectiveness of CoronaVac phase 3 clinical test. Later in the same day, PT Bio Farma added that the effective rate of Sinovac Biotech vaccinations has not yet been determined and claimed that the complete report will release in Jan 2021. Both parties did not explain the reason for misunderstanding.
Source: Stand News #Dec09
https://bit.ly/2K6ghES
#Indonesia #Beijing #SinovacBiotech #CoronaVac #Vaccination #Validity #Effectiveness #COVID19 #Phase3ClinicalTest
Brazil, Turkey and countries in East Asia Regions subsequently purchased Chinese COVID-19 vaccination which the foreign press claims it as “Chinese Vaccination Diplomatic”. Indonesia is the most frontline among these countries as they have received 1.2 million doses of CoronaVac, COVID-19 vaccinations from Sinovac Biotech in Beijing. However, Bio Forma Company, an Indonesia state-owned pharmaceutical company, pointed yesterday (Dec 8) that according to their interim data, the CoronaVac achieves 97% effectiveness, but then changed their wordings to uncertain protectiveness of the vaccine less than a day after.
An Indonesian state-owned pharmaceutical factory PT Bio Farma, co-operating with Beijing Sinovac Biotech, has announced on Tuesday (Dec 8) that the interim data of CoronaVoc phase 3 clinical test shows its 97% of effective protection without providing details.
Sinovac Biotech immediately issued a statement that they have not received data on the effectiveness of CoronaVac phase 3 clinical test. Later in the same day, PT Bio Farma added that the effective rate of Sinovac Biotech vaccinations has not yet been determined and claimed that the complete report will release in Jan 2021. Both parties did not explain the reason for misunderstanding.
Source: Stand News #Dec09
https://bit.ly/2K6ghES
#Indonesia #Beijing #SinovacBiotech #CoronaVac #Vaccination #Validity #Effectiveness #COVID19 #Phase3ClinicalTest
WHO Experts Review the Severe Side Effects Data of Sinovac, Commented "Low Credibility" for Elderly
WHO experts indicated 5 May that the Chinese Sinovac for COVID-19 has protection to adults who are under 60. However, there is a lack of data on the risk of serious side effects from vaccines, with “low credibility” for patients over aged 60 and with chronic illnesses. The expert group even referred to the severe side effect data of Sinovac on the elderly and patients with chronic illness as “very low” credibility.
The Strategic Advisory Group of Experts on Immunization (SAGE) in WHO evaluated the Phase 3 clinical test data of Sinovac in China, Brazil, Indonesia, Turkey, and Chile. They are very confident about the effectiveness of two doses of Sinovac in preventing adults aged 18-59, moderately confident about the severe side effect data on adults aged 59 years or younger. However, for those aged 60 years or older and patients with chronic diseases, the risk data of patients with severe side effects after vaccination is classified as “low credibility”, which means that the test data of Sinovac cannot determine the risks of serious side effects of Sinovac on the elderly and patients.
Source: Stand News #May06
https://bit.ly/3tKkLl3
#WHO #Vaccine #SAGE #COVID19 #China #Sinovac #Brazil #Indonesia #Turkey #Chile #Credibility #Phase3ClinicalTest
WHO experts indicated 5 May that the Chinese Sinovac for COVID-19 has protection to adults who are under 60. However, there is a lack of data on the risk of serious side effects from vaccines, with “low credibility” for patients over aged 60 and with chronic illnesses. The expert group even referred to the severe side effect data of Sinovac on the elderly and patients with chronic illness as “very low” credibility.
The Strategic Advisory Group of Experts on Immunization (SAGE) in WHO evaluated the Phase 3 clinical test data of Sinovac in China, Brazil, Indonesia, Turkey, and Chile. They are very confident about the effectiveness of two doses of Sinovac in preventing adults aged 18-59, moderately confident about the severe side effect data on adults aged 59 years or younger. However, for those aged 60 years or older and patients with chronic diseases, the risk data of patients with severe side effects after vaccination is classified as “low credibility”, which means that the test data of Sinovac cannot determine the risks of serious side effects of Sinovac on the elderly and patients.
Source: Stand News #May06
https://bit.ly/3tKkLl3
#WHO #Vaccine #SAGE #COVID19 #China #Sinovac #Brazil #Indonesia #Turkey #Chile #Credibility #Phase3ClinicalTest